HRP20100477T1 - Kemijski spojevi - Google Patents
Kemijski spojevi Download PDFInfo
- Publication number
- HRP20100477T1 HRP20100477T1 HR20100477T HRP20100477T HRP20100477T1 HR P20100477 T1 HRP20100477 T1 HR P20100477T1 HR 20100477 T HR20100477 T HR 20100477T HR P20100477 T HRP20100477 T HR P20100477T HR P20100477 T1 HRP20100477 T1 HR P20100477T1
- Authority
- HR
- Croatia
- Prior art keywords
- formula
- compound
- cancer
- 6alkyl
- alkyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract 38
- 238000000034 method Methods 0.000 claims abstract 9
- 206010028980 Neoplasm Diseases 0.000 claims abstract 6
- 201000011510 cancer Diseases 0.000 claims abstract 6
- 238000011282 treatment Methods 0.000 claims abstract 4
- -1 nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl Chemical group 0.000 claims 30
- 150000003839 salts Chemical class 0.000 claims 22
- 125000000217 alkyl group Chemical group 0.000 claims 20
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 12
- 125000000623 heterocyclic group Chemical group 0.000 claims 12
- 229910052739 hydrogen Inorganic materials 0.000 claims 11
- 239000001257 hydrogen Substances 0.000 claims 11
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims 9
- 125000005843 halogen group Chemical group 0.000 claims 9
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 9
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 8
- 229910052799 carbon Inorganic materials 0.000 claims 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 8
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 8
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims 7
- 125000001589 carboacyl group Chemical group 0.000 claims 7
- 229910052757 nitrogen Inorganic materials 0.000 claims 7
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 6
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 6
- 125000004452 carbocyclyl group Chemical group 0.000 claims 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 6
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 5
- 125000004845 (C1-C6) alkylsulfonylamino group Chemical group 0.000 claims 5
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims 5
- 125000003545 alkoxy group Chemical group 0.000 claims 5
- 206010006187 Breast cancer Diseases 0.000 claims 4
- 208000026310 Breast neoplasm Diseases 0.000 claims 4
- 206010027406 Mesothelioma Diseases 0.000 claims 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 4
- 206010041067 Small cell lung cancer Diseases 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 201000001441 melanoma Diseases 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 4
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 4
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 238000011321 prophylaxis Methods 0.000 claims 3
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 206010065859 Congenital fibrosarcoma Diseases 0.000 claims 2
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 2
- 206010062904 Hormone-refractory prostate cancer Diseases 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 206010070665 Mesoblastic nephroma Diseases 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 2
- 206010029260 Neuroblastoma Diseases 0.000 claims 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 206010033701 Papillary thyroid cancer Diseases 0.000 claims 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 206010038389 Renal cancer Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 2
- 125000004423 acyloxy group Chemical group 0.000 claims 2
- 230000001028 anti-proliverative effect Effects 0.000 claims 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 2
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims 2
- 201000010881 cervical cancer Diseases 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 2
- 201000010982 kidney cancer Diseases 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 claims 2
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 claims 2
- 230000003248 secreting effect Effects 0.000 claims 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 201000002510 thyroid cancer Diseases 0.000 claims 2
- 208000030045 thyroid gland papillary carcinoma Diseases 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- FDVYXPGZCFFAOV-KRWDZBQOSA-N (2r)-2-[5-[(5-cyclopropyl-1h-pyrazol-3-yl)amino]imidazo[4,5-b]pyridin-3-yl]-2-(4-fluorophenyl)ethanol Chemical compound C1([C@H](CO)N2C3=NC(NC4=NNC(=C4)C4CC4)=CC=C3N=C2)=CC=C(F)C=C1 FDVYXPGZCFFAOV-KRWDZBQOSA-N 0.000 claims 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 1
- WEMUXEAHYIJLLC-LBPRGKRZSA-N 6-chloro-3-[(1s)-1-(4-fluorophenyl)ethyl]-n-(3-propan-2-yloxy-1h-pyrazol-5-yl)imidazo[4,5-b]pyridin-5-amine Chemical class N1C(OC(C)C)=CC(NC=2C(=CC=3N=CN(C=3N=2)[C@@H](C)C=2C=CC(F)=CC=2)Cl)=N1 WEMUXEAHYIJLLC-LBPRGKRZSA-N 0.000 claims 1
- AEYYBNYJLOJJRE-NSHDSACASA-N 6-chloro-n-(5-cyclopropyl-1h-pyrazol-3-yl)-3-[(1s)-1-(4-fluorophenyl)ethyl]imidazo[4,5-b]pyridin-5-amine Chemical class C1([C@H](C)N2C3=NC(NC4=NNC(=C4)C4CC4)=C(Cl)C=C3N=C2)=CC=C(F)C=C1 AEYYBNYJLOJJRE-NSHDSACASA-N 0.000 claims 1
- GTQWPQWZQDJIDK-LBPRGKRZSA-N 6-fluoro-3-[(1s)-1-(4-fluorophenyl)ethyl]-n-(3-propan-2-yloxy-1h-pyrazol-5-yl)imidazo[4,5-b]pyridin-5-amine Chemical class N1C(OC(C)C)=CC(NC=2C(=CC=3N=CN(C=3N=2)[C@@H](C)C=2C=CC(F)=CC=2)F)=N1 GTQWPQWZQDJIDK-LBPRGKRZSA-N 0.000 claims 1
- PGJIKVGJKHTQEB-NSHDSACASA-N 6-fluoro-3-[(1s)-1-(4-fluorophenyl)ethyl]-n-(5-methyl-1h-pyrazol-3-yl)imidazo[4,5-b]pyridin-5-amine Chemical class C1([C@H](C)N2C3=NC(NC4=NNC(C)=C4)=C(F)C=C3N=C2)=CC=C(F)C=C1 PGJIKVGJKHTQEB-NSHDSACASA-N 0.000 claims 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 150000002118 epoxides Chemical class 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 201000005619 esophageal carcinoma Diseases 0.000 claims 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000006125 ethylsulfonyl group Chemical group 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims 1
- ZJKJHYMHERVKGZ-LBPRGKRZSA-N n-(5-cyclopropyl-1h-pyrazol-3-yl)-3-[(1s)-1-(4-fluorophenyl)ethyl]imidazo[4,5-b]pyridin-5-amine Chemical compound C1([C@H](C)N2C3=NC(NC4=NNC(=C4)C4CC4)=CC=C3N=C2)=CC=C(F)C=C1 ZJKJHYMHERVKGZ-LBPRGKRZSA-N 0.000 claims 1
- GBEMGSXBITUWBG-NSHDSACASA-N n-(5-cyclopropyl-1h-pyrazol-3-yl)-6-fluoro-3-[(1s)-1-(4-fluorophenyl)ethyl]imidazo[4,5-b]pyridin-5-amine Chemical class C1([C@H](C)N2C3=NC(NC4=NNC(=C4)C4CC4)=C(F)C=C3N=C2)=CC=C(F)C=C1 GBEMGSXBITUWBG-NSHDSACASA-N 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 125000006239 protecting group Chemical group 0.000 claims 1
- 235000010288 sodium nitrite Nutrition 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US65333005P | 2005-02-16 | 2005-02-16 | |
| US73296505P | 2005-11-03 | 2005-11-03 | |
| PCT/GB2006/000522 WO2006087538A1 (en) | 2005-02-16 | 2006-02-15 | Chemical compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20100477T1 true HRP20100477T1 (hr) | 2010-10-31 |
Family
ID=36129856
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20100477T HRP20100477T1 (hr) | 2005-02-16 | 2010-08-31 | Kemijski spojevi |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US7622482B2 (da) |
| EP (1) | EP1853602B1 (da) |
| JP (1) | JP2008530191A (da) |
| KR (1) | KR20070104936A (da) |
| AT (1) | ATE473975T1 (da) |
| AU (1) | AU2006215394B2 (da) |
| BR (1) | BRPI0608160A2 (da) |
| CA (1) | CA2598076A1 (da) |
| CY (1) | CY1110900T1 (da) |
| DE (1) | DE602006015431D1 (da) |
| DK (1) | DK1853602T3 (da) |
| ES (1) | ES2347172T3 (da) |
| HK (1) | HK1113352A1 (da) |
| HR (1) | HRP20100477T1 (da) |
| IL (1) | IL184872A0 (da) |
| MX (1) | MX2007009842A (da) |
| NO (1) | NO20073790L (da) |
| NZ (1) | NZ561526A (da) |
| PL (1) | PL1853602T3 (da) |
| PT (1) | PT1853602E (da) |
| SI (1) | SI1853602T1 (da) |
| WO (1) | WO2006087538A1 (da) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL1846394T3 (pl) | 2005-02-04 | 2012-04-30 | Astrazeneca Ab | Pochodne pirazoliloaminopirydyny użyteczne jako inhibitory kinazy |
| KR101362621B1 (ko) | 2005-02-16 | 2014-02-13 | 아스트라제네카 아베 | 화합물 |
| PT1945631E (pt) | 2005-10-28 | 2012-10-15 | Astrazeneca Ab | Derivados de 4-(3-aminopirazole)pirimidina para utilização como inibidores da tirosina-cinase no tratamento do cancro |
| US7989459B2 (en) | 2006-02-17 | 2011-08-02 | Pharmacopeia, Llc | Purinones and 1H-imidazopyridinones as PKC-theta inhibitors |
| US7767685B2 (en) * | 2006-06-29 | 2010-08-03 | King Pharmaceuticals Research And Development, Inc. | Adenosine A2B receptor antagonists |
| CL2007002866A1 (es) | 2006-10-04 | 2008-07-04 | Pharmacopeia Inc | Compuestos derivados de 6-sustituidos-2-(bencimidazolil) purina y purinona; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de enfermedades autoinmunes, enfermedad inflamatoria, enfermedad mediada por m |
| US7902187B2 (en) | 2006-10-04 | 2011-03-08 | Wyeth Llc | 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression |
| US7915268B2 (en) | 2006-10-04 | 2011-03-29 | Wyeth Llc | 8-substituted 2-(benzimidazolyl)purine derivatives for immunosuppression |
| ZA200902382B (en) * | 2006-10-19 | 2010-08-25 | Signal Pharm Llc | Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors |
| EP2155742A1 (en) * | 2007-04-18 | 2010-02-24 | AstraZeneca AB | 5-aminopyrazol-3-yl-3h-imidazo [4,5-b]pyridine derivatives and their use for the treatment of cancer |
| CA2686485A1 (en) * | 2007-05-23 | 2008-11-27 | Pharmacopeia, Llc | Purinones and 1h-imidazopyridinones as pkc-theta inhibitors |
| JP2011505407A (ja) * | 2007-12-03 | 2011-02-24 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 過剰な又は異常な細胞増殖を特徴とする疾患を治療するためのジアミノピリジン |
| CA2738026C (en) * | 2008-09-22 | 2017-01-24 | Array Biopharma Inc. | Substituted imidazo[1,2b]pyridazine compounds as trk kinase inhibitors |
| AU2015200511B2 (en) * | 2008-10-22 | 2017-08-31 | Array Biopharma Inc. | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS |
| DK3106463T6 (da) | 2008-10-22 | 2020-02-24 | Array Biopharma Inc | Pyrazolo[1,5-]pyrimidinforbindelse som trk-kinasehæmmer |
| PA8851101A1 (es) | 2008-12-16 | 2010-07-27 | Lilly Co Eli | Compuesto amino pirazol |
| WO2010088924A1 (en) | 2009-02-06 | 2010-08-12 | Telormedix Sa | Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration |
| AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
| CN106432225B (zh) | 2009-12-31 | 2019-02-19 | 和记黄埔医药（上海）有限公司 | 某些三唑并吡啶化合物和三唑并吡嗪化合物、其组合物和其使用方法 |
| JP2013519719A (ja) | 2010-02-18 | 2013-05-30 | セントロ ナシオナル デ インベスティガシオネス オンコロヒカス（セエネイオ） | トリアゾロ［４，５−ｂ］ピリジン誘導体 |
| US9050319B2 (en) | 2010-04-30 | 2015-06-09 | Telormedix, Sa | Phospholipid drug analogs |
| AU2011247358B2 (en) | 2010-04-30 | 2014-10-30 | Urogen Pharma Ltd. | Phospholipid drug analogs |
| HUE035337T2 (en) | 2010-05-20 | 2018-05-02 | Array Biopharma Inc | Macrocyclic compounds as TRK kinase inhibitors |
| WO2012097478A1 (en) * | 2011-01-21 | 2012-07-26 | Abbott Laboratories | Bicyclic carboxamide inhibitors of kinases |
| WO2013009582A1 (en) | 2011-07-12 | 2013-01-17 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF |
| US9365556B2 (en) | 2012-03-16 | 2016-06-14 | Axikin Pharmaceuticals, Inc. | 3,5-diaminopyrazole kinase inhibitors |
| WO2013176970A1 (en) | 2012-05-22 | 2013-11-28 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF |
| TWI585088B (zh) | 2012-06-04 | 2017-06-01 | 第一三共股份有限公司 | 作爲激酶抑制劑之咪唑并［１，２－ｂ］嗒衍生物 |
| US20160222014A1 (en) * | 2013-09-10 | 2016-08-04 | Asana Biosciences, Llc | Compounds for regulating fak and/or src pathways |
| NZ631142A (en) | 2013-09-18 | 2016-03-31 | Axikin Pharmaceuticals Inc | Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors |
| WO2015039333A1 (en) | 2013-09-22 | 2015-03-26 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF |
| WO2015039334A1 (en) | 2013-09-22 | 2015-03-26 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF |
| WO2015143652A1 (en) | 2014-03-26 | 2015-10-01 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF |
| WO2015143653A1 (en) | 2014-03-26 | 2015-10-01 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF |
| WO2015143654A1 (en) | 2014-03-26 | 2015-10-01 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF |
| DK3699181T3 (da) | 2014-11-16 | 2023-03-20 | Array Biopharma Inc | Krystallinsk form af (s)-n-(5-((r)-2-(2,5-difluorphenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidin-1-carboxamidhydrogensulfat |
| US9546163B2 (en) | 2014-12-23 | 2017-01-17 | Axikin Pharmaceuticals, Inc. | 3,5-diaminopyrazole kinase inhibitors |
| WO2016161572A1 (en) | 2015-04-08 | 2016-10-13 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF |
| TN2018000138A1 (en) | 2015-10-26 | 2019-10-04 | Array Biopharma Inc | Point mutations in trk inhibitor-resistant cancer and methods relating to the same |
| US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
| MA44612A (fr) | 2016-04-04 | 2019-02-13 | Loxo Oncology Inc | Méthodes de traitement de cancers pédiatriques |
| PE20181888A1 (es) | 2016-04-04 | 2018-12-11 | Loxo Oncology Inc | Formulaciones liquidas de (s)-n-(5-((r)-2-(2,5-difluorofenil)-pirrolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida |
| EP3800189B1 (en) | 2016-05-18 | 2023-06-28 | Loxo Oncology, Inc. | Preparation of (s)-n-(5-((r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide |
| JP7029444B2 (ja) | 2016-08-22 | 2022-04-07 | メッドシャイン ディスカバリー インコーポレイテッド | Ｐｄｅ４阻害剤 |
| JOP20190092A1 (ar) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها |
| JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
| CN112739691B (zh) | 2018-09-03 | 2023-05-23 | 泰励生物科技（上海）有限公司 | 用作抗癌药的trk抑制剂 |
| US20220143049A1 (en) | 2019-03-21 | 2022-05-12 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| JP2023500906A (ja) | 2019-11-08 | 2023-01-11 | インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） | キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| CN113278022B (zh) * | 2020-07-07 | 2023-12-12 | 南京纳丁菲医药科技有限公司 | 吡唑并嘧啶化合物和药物组合物及其应用 |
| CN115141195B (zh) * | 2021-03-03 | 2024-02-06 | 成都先导药物开发股份有限公司 | 一种nuak抑制剂及其用途 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6399780B1 (en) * | 1999-08-20 | 2002-06-04 | Cephalon, Inc. | Isomeric fused pyrrolocarbazoles and isoindolones |
| US20030105090A1 (en) * | 2000-12-21 | 2003-06-05 | David Bebbington | Pyrazole compounds useful as protein kinase inhibitors |
| EP1383731B1 (en) * | 2001-04-06 | 2009-08-05 | Biocryst Pharmaceuticals, Inc. | Biaryl compounds as serine protease inhibitors |
| ATE343575T1 (de) * | 2001-09-27 | 2006-11-15 | Smithkline Beecham Corp | Azaoxoindol derivate als trk protein kinase hemmstoffe zur behandlung von krebs und chronischem schmerz |
-
2006
- 2006-02-15 AU AU2006215394A patent/AU2006215394B2/en not_active Ceased
- 2006-02-15 DK DK06709759.2T patent/DK1853602T3/da active
- 2006-02-15 KR KR1020077021200A patent/KR20070104936A/ko not_active Application Discontinuation
- 2006-02-15 AT AT06709759T patent/ATE473975T1/de active
- 2006-02-15 CA CA002598076A patent/CA2598076A1/en not_active Abandoned
- 2006-02-15 PT PT06709759T patent/PT1853602E/pt unknown
- 2006-02-15 BR BRPI0608160-6A patent/BRPI0608160A2/pt not_active IP Right Cessation
- 2006-02-15 JP JP2007555690A patent/JP2008530191A/ja active Pending
- 2006-02-15 WO PCT/GB2006/000522 patent/WO2006087538A1/en active Application Filing
- 2006-02-15 DE DE602006015431T patent/DE602006015431D1/de active Active
- 2006-02-15 PL PL06709759T patent/PL1853602T3/pl unknown
- 2006-02-15 MX MX2007009842A patent/MX2007009842A/es not_active Application Discontinuation
- 2006-02-15 ES ES06709759T patent/ES2347172T3/es active Active
- 2006-02-15 EP EP06709759A patent/EP1853602B1/en active Active
- 2006-02-15 SI SI200630760T patent/SI1853602T1/sl unknown
- 2006-02-15 NZ NZ561526A patent/NZ561526A/en not_active IP Right Cessation
- 2006-02-15 US US11/816,376 patent/US7622482B2/en not_active Expired - Fee Related
-
2007
- 2007-07-20 NO NO20073790A patent/NO20073790L/no not_active Application Discontinuation
- 2007-07-26 IL IL184872A patent/IL184872A0/en unknown
-
2008
- 2008-03-07 HK HK08102714.3A patent/HK1113352A1/xx not_active IP Right Cessation
-
2010
- 2010-08-31 HR HR20100477T patent/HRP20100477T1/hr unknown
- 2010-09-09 CY CY20101100825T patent/CY1110900T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SI1853602T1 (sl) | 2010-11-30 |
| CA2598076A1 (en) | 2006-08-24 |
| BRPI0608160A2 (pt) | 2010-11-09 |
| EP1853602B1 (en) | 2010-07-14 |
| PL1853602T3 (pl) | 2010-11-30 |
| CY1110900T1 (el) | 2015-06-10 |
| NZ561526A (en) | 2010-11-26 |
| HK1113352A1 (en) | 2008-10-03 |
| US20090137624A1 (en) | 2009-05-28 |
| AU2006215394B2 (en) | 2009-10-08 |
| KR20070104936A (ko) | 2007-10-29 |
| IL184872A0 (en) | 2007-12-03 |
| ATE473975T1 (de) | 2010-07-15 |
| MX2007009842A (es) | 2007-08-23 |
| DE602006015431D1 (de) | 2010-08-26 |
| WO2006087538A1 (en) | 2006-08-24 |
| US7622482B2 (en) | 2009-11-24 |
| DK1853602T3 (da) | 2010-09-20 |
| AU2006215394A1 (en) | 2006-08-24 |
| JP2008530191A (ja) | 2008-08-07 |
| PT1853602E (pt) | 2010-08-25 |
| NO20073790L (no) | 2007-09-03 |
| EP1853602A1 (en) | 2007-11-14 |
| ES2347172T3 (es) | 2010-10-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20100477T1 (hr) | Kemijski spojevi | |
| HRP20110962T1 (hr) | Derivati pirazolil-aminopiridina korisni kao inhibitori kinaze | |
| RU2007134396A (ru) | Химические соединения | |
| AR046779A1 (es) | Derivados de pirazol, metodos para su preparacion y usos de los mismos en la fabricacion de composiciones farmaceuticas y medicamentos que los contienen con actividad inhibitoria de trk para el tratamiento o profilaxis del cancer. | |
| AR063643A1 (es) | Compuestos quimicos derivados de quinolina, un metodo de preparacion y composiciones farmaceuticas | |
| AR049662A1 (es) | Derivados de 1,3-fenilendiamina con efecto inhibitorio de b-raf; un metodo para su preparacion, composiciones farmaceuticas que los contienen y su utilizacion en la fabricacion de medicamentos para el tratamiento del cancer | |
| AR054183A1 (es) | Derivados de piridincarboxamida y su uso como agentes anticancerigenos. procesos de obtencion y composiciones farmaceuticas. | |
| AR056354A1 (es) | DERIVADOS DE PIRAZOL, UN MÉTODO DE PREPARACIoN DEL COMPUESTO, COMPOSICIoN FARMACÉUTICA Y PREPARACIoN DE UN MEDICAMENTO | |
| AR056556A1 (es) | Imidazo(1,2-a)piridina con actividad antiproliferacion celular | |
| AR053992A1 (es) | Compuestos quimicos con actividad anticancerosa, un procedimiento para su preparacion, su uso en la preparacion de medicamentos y composicion farmaceutica. | |
| ME01488B (me) | Derivati oksadiazola i njihovo korišćenje kao potencijatora metabotropnih glutamatnih receptora-842 | |
| EA200702497A1 (ru) | Замещенные арилпиразолы для применения против паразитов | |
| WO2008048981A3 (en) | Indole antagonists of p2y1 receptor useful in the treatment of thrombotic conditions | |
| MX2007005189A (es) | Derivados de quinuclidina y su uso como antagonistas del receptor muscarinico m3. | |
| ATE483707T1 (de) | 2-cyclopropylthiazolderivate | |
| UA92670C2 (ru) | Пиразолиновые соединения и их фармацевтическое применение, композиция на их основе | |
| TW200604183A (en) | Triazole compounds and their use as metabotropic glutamate receptor antagonists | |
| AR050545A1 (es) | Derivados de quinazolinonas y su uso como inhibidores de b-raf | |
| JP2012509263A5 (da) | ||
| AR046616A1 (es) | Piperidinas sustituidas utiles en el tratamiento de sindrome metabolico | |
| UY30310A1 (es) | Derivados 2-azetidinona, sales, solvatos, composiciones farmacéuticas conteniéndolos, procesos de preparacion y aplicaciones | |
| MX2010001338A (es) | Derivados de pirimidina y piridina y su uso y composiciones farmaceuticas. | |
| AR061118A1 (es) | Derivados de pirimidina, un proceso para su preparacion, composiciones farmaceuticas que los comprenden y el uso de los mismos en la fabricacion de medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de cdk2. | |
| JP2015504076A5 (da) | ||
| TW200639156A (en) | New compounds |